Nivolumab activity in advanced refractory malignant peritoneal mesothelioma

Malignant peritoneal mesothelioma is a rare neoplasm of mesothelial origin characterised by the diffuse invasion of peritoneal surfaces and a devastating prognosis. The therapeutic approach usually consists in cytoreductive surgery whenever feasible, with or without intraperitoneal or systemic perioperative chemotherapy [1]. For unresectable tumours, chemotherapy with pemetrexed and cisplatin, often in combination with bevacizumab, has become the most frequently used systemic therapy, based on the results observed in malignant pleural mesothelioma [2].

Lascia un commento